A Phase 2 interventional study of Celecoxib and Celecoxib in Pain, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 22 sites in Japan. Open to participants aged 20 Years to 64 Years. Per ClinicalTrials.gov, last updated 2021-02-02.
Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies testing celecoxib in Pain — none open to participants now, 1 under way, none of them phase 3. Celecoxib · Pain.
Among the 22 studies testing celecoxib in Pain, this one is the 3rd largest by enrollment, is one of 2 that started in 2010, is one of 5 in phase 2, and was the 9th registered.
10,069 studies on the registry are indexed under Pain; 1,651 are open to participants now.
Browse Pain studies →None of the 22 studies testing celecoxib in Pain is open now. The open studies under Pain, anywhere →
Celecoxib: first FDA approval 1998 (CELEBREX), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →
Of the 928 Pain studies recruiting now, 383 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 222 take healthy volunteers.
This study: 20 Years to 64 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 2 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 255 is above the median of 66 across 8,502 interventional studies indexed under Pain.
Median enrollment 79 across the 22 interventional studies. Of the 16 that completed or were terminated, 6 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 22 have an industry lead sponsor. The 10 most frequent:
This study is registered under Pfizer's Upjohn has merged with Mylan to form Viatris Inc., one of the names counted as Viatris Inc.. Under that name alone:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. is the lead sponsor of 434 studies on the registry; none are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 8 (89%) have results posted.
22 studies in Pain by Viatris Inc.: none open now, none under way, none of them phase 3. Of 22 finished, 18 (82%) have results posted.
Among the 22 studies in Pain by Viatris Inc., this one is the 7th largest by enrollment of the 20 interventional ones that give a count, is one of 4 that started in 2010, is one of 3 in phase 2, and was the 12th registered.
Viatris Inc.’s Pain studies by the year they started, since 2006.
None of the studies under way reaches primary completion within a year.
Among the 22 studies testing celecoxib in Pain, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Viatris Inc.’s 22 in Pain:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To evaluate efficacy and safety of additional dose of celecoxib, as compared to placebo, in patients with post lateral mandibular impacted third molar tooth extraction pain.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Initial dose:
Additional dose:
Exclusion Criteria:
Drug: Celecoxib
Drug: Celecoxib
Drug: Placebo
Initial dose: Celecoxib 200mg tablet x 2 will be administrated during a period from 1 to 2 hours post lateral mandibular impacted third molar tooth extraction in subjects with "moderate pain" or "severe pain"rated as 45.0 mm or more on the VAS
Additional dose: Celecoxib 200mg tablet x 1 will be administrated during a period from 5 to 12 hours post-initial dose of Celecoxib 400mg in subjects who require an additional analgesic dose for any pain
Additional dose: Placebo (tablet) will be administrated during a period from 5 to 12 hours post-initial dose of Celecoxib 400mg in subjects who require an additional analgesic dose for any pain
Efficacy Rate (Percentage) of Patient's Impression
Patient's impression was assessed by self-report and was entered in the patient diary, based on the following categories: "Excellent", " Good", "Fair" and "Poor". Efficacy rate was calculated from the following formula, "The number of participants assessed as Excellent or Good" over "total participants" multiplied by 100.
Time frame: 2 hours post-additional dose
Number of Participants in Each Pain Intensity (PI) With 4 Categories
Pain intensity was entered in the patient diary on the following categories: "No pain", "Mild pain", "Moderate pain" and "Severe pain".
Time frame: 2 hours after additional dose
Pain Intensity Measured by Visual Analog Scale (VAS)
The Pain intensity was recorded on the 100 mm VAS in the patient diary, where 0 mm=no pain, 100 mm=unbearable maximal pain.
Time frame: 2 hours post-additional dose
Differences in Pain Intensity (PI) Measured by VAS Among Participants
The differences in PI were obtained by subtracting the PI at each time point from the Baseline PI score.
Time frame: Pre-additional dose (baseline) and 2 hours post-additional dose
| Milestone | Initial Dose Celecoxib 400 mg | Additional Dose Celecoxib 200 mg | Additional Dose Placebo |
|---|---|---|---|
| Started | 133 | 64 | 58 |
| Completed | 93 | 42 | 27 |
| Not completed | 40 | 22 | 31 |
| Withdrew: Adverse event | 1 | 0 | 0 |
| Withdrew: Lack of efficacy | 38 | 22 | 31 |
| Withdrew: Withdrawal by subject | 1 | 0 | 0 |
Patient's impression was assessed by self-report and was entered in the patient diary, based on the following categories: "Excellent", " Good", "Fair" and "Poor". Efficacy rate was calculated from the following formula, "The number of participants assessed as Excellent or Good" over "total participants" multiplied by 100.
| percentage of participants | Additional Dose Celecoxib 200 mg | Additional Dose Placebo |
|---|---|---|
| Efficacy Rate (Percentage) of Patient's Impression | 64.1 | 25.9 |
Pain intensity was entered in the patient diary on the following categories: "No pain", "Mild pain", "Moderate pain" and "Severe pain".
| participants | Additional Dose Celecoxib 200mg | Additional Dose Placebo |
|---|---|---|
| None | 11 | 3 |
| Mild | 34 | 24 |
| Moderate | 18 | 28 |
| Severe | 1 | 3 |
The Pain intensity was recorded on the 100 mm VAS in the patient diary, where 0 mm=no pain, 100 mm=unbearable maximal pain.
| mm | Additional Dose Celecoxib 200 mg | Additional Dose Placebo |
|---|---|---|
| Pain Intensity Measured by Visual Analog Scale (VAS) | 35.8 ± 25.5 | 51.9 ± 21.9 |
The differences in PI were obtained by subtracting the PI at each time point from the Baseline PI score.
| mm | Additional Dose Celecoxib 200 mg | Additional Dose Placebo |
|---|---|---|
| Differences in Pain Intensity (PI) Measured by VAS Among Participants | 33.4 ± 24.2 | 12.3 ± 19.5 |
Collected over From informed consent to Day 28 postdose. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Initial Dose Celecoxib 400 mg | — | 0/133 (0%) | 25/133 (18.8%) |
| Additional Dose Celecoxib 200 mg | — | 0/64 (0%) | 13/64 (20.3%) |
| Additional Dose Placebo | — | 0/58 (0%) | 18/58 (31%) |
| Event | Initial Dose Celecoxib 400 mg | Additional Dose Celecoxib 200 mg | Additional Dose Placebo |
|---|---|---|---|
| Beta 2 microglobulin increasedInvestigations | 7/133 | 5/64 | 9/58 |
| Beta-N-acetyl-D-glucosaminidase increasedInvestigations | 4/133 | 1/64 | 5/58 |
| Blood bilirubin increasedInvestigations | 4/133 | 3/64 | 1/58 |
| Blood phosphorus increasedInvestigations | 0/133 | 0/64 | 2/58 |
| White blood cell count increasedInvestigations | 1/133 | 1/64 | 2/58 |
| Blood creatine phosphokinase increasedInvestigations | 1/133 | 1/64 | 1/58 |
| Blood urea increasedInvestigations | 0/133 | 0/64 | 1/58 |
| Protein urine presentInvestigations | 0/133 | 1/64 | 1/58 |
| Urobilin urine presentInvestigations | 1/133 | 1/64 | 1/58 |
| SomnolenceNervous system disorders | 1/133 | 1/64 | 1/58 |
| Age, Customized(participants) | Initial Dose Celecoxib 400 mg | Additional Dose Celecoxib 200 mg | Additional Dose Placebo | Total |
|---|---|---|---|---|
| < 18 years | 0 | 0 | 0 | 0 |
| Between 18 and 64 | 133 | 64 | 58 | 255 |
| >= 65 years | 0 | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | Initial Dose Celecoxib 400 mg | Additional Dose Celecoxib 200 mg | Additional Dose Placebo | Total |
|---|---|---|---|---|
| Female | 64 | 39 | 36 | 139 |
| Male | 69 | 25 | 22 | 116 |
The record gives a start of Apr 2010, a primary completion of Aug 2010 and a completion of Aug 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2012, 2 years 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Celecoxib
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. →